|Day Low/High||64.03 / 64.92|
|52 Wk Low/High||48.58 / 65.90|
Jim Cramer says investors should turn this Turkey-induced selloff into a buying opportunity.
It is all about perception, and here are strong names to pick up on market weakness.
Markets edged higher in what was a busy week from both a political and economic perspective.
- FDA approval of new software upgrade for Abbott's deep brain stimulation therapy enables advanced, patient-centric features for people living with Parkinson's disease and essential tremor
Jim Cramer says the tide of selling eventually ebbs, and when it does, stocks rally.
Jim Cramer takes a closer look at IDEXX Labs, Evolent Health, Triton, Western Gas Partners, Zimmer Biomet and more.
As hedge funds are forced to unwind tech positions, here is how to play the rotation.
- ALLOWS USERS TO WEAR THE SENSOR FOR UP TO 14 DAYS WITH HIGH ACCURACY
- Investigational Tendyne device is first and only repositionable and fully retrievable mitral valve replacement
New Officers and Directors Bring Extensive Medical Company Growth Experience to ViewRay
Jim Cramer says tariffs and trade could be tough on some stocks, but he's optimistic about earnings season.
We raised our price targets on four positions after their latest earnings reports.
Earnings have been strong, and analysts will soon start to concentrate more on actual weakness than shadow-boxing weakness.
Stocks moved up this week as earnings season got underway and investors shrugged off more trade war threats from President Trump.
Drug pricing remains front and center as healthcare companies start reporting quarterly results.
Jim Cramer says financial payment companies are the most beloved in the market right now. He explains digitized payment companies. And love.
Jim discusses his interview with Larry Kudlow at the Delivering Alpha conference, Nucor's earnings, Danaher's earnings and announced spin, Abbott Labs, and Comcast!
The Dow and S&P 500 held onto modest gains at the close, while the Nasdaq ended flat following the second day of Congressional testimony from Fed Chairman Jerome Powell Wednesday.
If you are long ABT continue to hold and raise sell stop protection to a close below $59 or where the 200-day moving average line intersects.
The company is on track for another terrific year of double digit earnings per share growth.
The Abbott Park, Ill., healthcare company beats top- and bottom-line estimates and raises its full-year outlook for earnings.
This group is expected to post second-quarter EPS gains of 30%; here is how to trade it.
- Second-quarter reported sales growth of 17.0 percent; GAAP EPS from continuing operations of $0.40
U.S. stock futures are flat on Wednesday, following an upbeat assessment of the U.S. economy from Federal Reserve Chairman Jerome Powell; Morgan Stanley and IBM report earnings; Google faces a record $5 billion fine from the European Union.
In April, CEO Miles White said the healthcare company had paid down $6 billion of debt this year and expected to pay down another $2 billion by the end of 2018.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.